Content » Vol 53, Issue 9

Original report

Effects of β-hydroxy-β-methylbutyrate supplementation on muscle mass and strength in onabotulinumtoxin type-A-injected and contralateral quadriceps femoris in rabbits

Rafael Fortuna, Andrew Sawatsky, John C. Fuller, Jr, Walter Herzog
Human Performance Laboratory, University of Calgary, Calgary, Canada.
DOI: 10.2340/16501977-2866


Objective: To determine the effects of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB) on strength, muscle mass, and contractile material in muscle wasting induced by onabotulinumtoxin type-A (BoNT-A) injection into the quadriceps femoris muscles of New Zealand white rabbits.
Methods: A total of 21, female rabbits were divided into 3 groups (n=7, each). Group 1 (Control) received intramuscular injection of saline. Groups 2 and 3 received intramuscular injection of BoNT-A (3.5 units/kg), with group 3 receiving supplementation with HMB (120 mg/kg-BW/day). Muscle morphology, mass, and strength were assessed 8 weeks later in both injected and non-injected contralateral limbs.
Results: Injected muscle strength of group 2 (BoNT-A) and group 3 (BoNT-A+HMB) was reduced by 63% and 60%, respectively, compared with Controls (p<0.0001). Strength in contralateral muscles of group 2 was reduced by 23% vs Controls (p<0.002), while in group 3, strength was similar to Controls. Muscle mass in the injected muscles of the BoNT-A and BoNT-A+HMB groups was significantly reduced, by 46% and 48%, respectively.
Conclusion: While HMB did not prevent loss of muscle strength and mass in the BoNT-A-injected musculature, it prevented significant loss of contractile material in the injected musculature and strength loss in the contralateral non-injected musculature.

Lay Abstract

Onabotulinum toxin A (BoNT-A) is currently approved for cosmetic procedures and for the treatment of many conditions, such as migraine headaches and neuromuscular conditions associated with spasticity, such as cerebral palsy or post-stroke in USA. Once injected into the muscle BoNT-A causes muscle paralysis, which is reversible. The current study examined the local and distant detrimental effects of BoNT-A on decreasing muscle wasting and muscle function in a rabbit model, and the effects of dietary use of HMB (β-hydroxy-β-methylbutyrate), a leucine metabolite, on these detrimental effects. BoNT-A was injected into 1 leg of a rabbit model and muscle mass and strength measured in both the injected and non-injected legs. BoNT-A caused a loss of muscle mass in the injected legs. It also caused a loss of strength in the injected legs and a somewhat reduced loss of strength in the non-injected legs. This suggests that BoNT-A injections can cause a decrease in function in distant, non-target muscles. HMB partially reversed some of the detrimental side-effects of BoNT-A, being shown to be effective in maintaining muscle strength in the non-injected leg.


Do you want to comment on this paper? The comments will show up here and if appropriate the comments will also separately be forwarded to the authors. You need to login/create an account to comment on articles. Click here to login/create an account.